Genomic and prognostic heterogeneity among RAS/BRAF^V600E /TP53 co-mutated resectable colorectal liver metastases.

ABSTRACT: Hepatic resection is potentially curative for patients with colorectal liver metastases, but the treatment benefit varies. KRAS/NRAS (RAS)/TP53 co-mutations are associated with a poor prognosis after resection, but there is large variation in patient outcome within the mutation groups, and genetic testing is currently not used to evaluate benefit from surgery. We have investigated the potential for improved prognostic stratification by combined biomarker analysis with DNA copy number aberrations (CNAs), and taking tumor heterogeneity into account. We determined the mutation status of RAS, BRAF^V600 , and TP53 in 441 liver lesions from 171 patients treated by partial hepatectomy for metastatic colorectal cancer. CNAs were profiled in 232 tumors from 67 of the patients. Mutations a

SUBMITTER: Berg KCG 

PROVIDER: S-EPMC8024718 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature